Eli Lilly has confirmed that it is at the forefront of a new era in the pharmaceutical industry. Second-quarter 2025 results mark the company's extraordinary form - sharp revenue growth, record profitability and a boosted outlook for the rest of the year have pushed the stock to all-time highs. The combination of a strong product portfolio, innovation in metabolic disease treatments and a robust research program makes it one of the most trusted companies today.

The company has been able to build on previous successes, but this time on an even larger scale. At a time when competitors are just expanding their development portfolio, Lilly is reaping the results of several years of work - its drugs have become synonymous with a new generation of pharmacological approaches and are rapidly changing market dynamics in key therapeutic segments. As a result, the company is not only growing, but also reshaping the very fabric of global pharma.

How was the last quarter?

The second quarter of 2025…